

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 29, 2001, 13:53:04 ; Search time 31.29 Seconds
(without alignments)
129.709 Million cell updates/sec

Title: US-09-537-859-3

Perfect score: 382
Sequence: 1 SIPTICGCVNIRKRIPIORL.....ERWYRDSKMDLIFQNLKP 71

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 390729 seqs, 57163235 residues

number of hits satisfying chosen parameters: 390729

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

A_Geneseq_0401:*

- 1: /SIDS6/gcgdata/geneseq/geneseqp/AA1980.DAT:*
- 2: /SIDS6/gcgdata/geneseq/geneseqp/AA1981.DAT:*
- 3: /SIDS6/gcgdata/geneseq/geneseqp/AA1982.DAT:*
- 4: /SIDS6/gcgdata/geneseq/geneseqp/AA1983.DAT:*
- 5: /SIDS6/gcgdata/geneseq/geneseqp/AA1984.DAT:*
- 6: /SIDS6/gcgdata/geneseq/geneseqp/AA1985.DAT:*
- 7: /SIDS6/gcgdata/geneseq/geneseqp/AA1986.DAT:*
- 8: /SIDS6/gcgdata/geneseq/geneseqp/AA1987.DAT:*
- 9: /SIDS6/gcgdata/geneseq/geneseqp/AA1988.DAT:*
- 10: /SIDS6/gcgdata/geneseq/geneseqp/AA1989.DAT:*
- 11: /SIDS6/gcgdata/geneseq/geneseqp/AA1990.DAT:*
- 12: /SIDS6/gcgdata/geneseq/geneseqp/AA1991.DAT:*
- 13: /SIDS6/gcgdata/geneseq/geneseqp/AA1992.DAT:*
- 14: /SIDS6/gcgdata/geneseq/geneseqp/AA1993.DAT:*
- 15: /SIDS6/gcgdata/geneseq/geneseqp/AA1994.DAT:*
- 16: /SIDS6/gcgdata/geneseq/geneseqp/AA1995.DAT:*
- 17: /SIDS6/gcgdata/geneseq/geneseqp/AA1996.DAT:*
- 18: /SIDS6/gcgdata/geneseq/geneseqp/AA1997.DAT:*
- 19: /SIDS6/gcgdata/geneseq/geneseqp/AA1998.DAT:*
- 20: /SIDS6/gcgdata/geneseq/geneseqp/AA1999.DAT:*
- 21: /SIDS6/gcgdata/geneseq/geneseqp/AA2000.DAT:*
- 22: /SIDS6/gcgdata/geneseq/geneseqp/AA2001.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	382	100.0	71	20	Y07234
2	382	100.0	71	20	Y07238
3	382	100.0	76	21	Y69031
4	382	100.0	77	21	B15786
5	382	100.0	99	20	Y05300
6	382	100.0	99	20	Y07233
7	382	100.0	99	20	Y07237
8	382	100.0	109	19	W42072
9	378	99.0	109	18	W26655
10	359	94.0	77	20	Y14223
11	344	90.1	72	16	R70804

12	267	69.9	74	21	Y69023	Amino acid sequenc
13	267	69.9	97	17	W00667	Pancreas expressed
14	267	69.9	97	18	W14980	Human eosinocyte C
15	267	69.9	97	21	W10099	Human ectaxin. Ho
16	267	69.9	97	21	B15794	Human chemokine eo
17	267	69.9	323	21	Y69058	A chemokine recept
18	267	69.9	325	21	Y69059	A chemokine recept
19	267	69.9	330	21	Y69060	A chemokine recept
20	246	64.4	69	18	W13586	Monocyte chemotatr
21	246	64.4	76	10	P90292	Peptide from human
22	246	64.4	76	13	R28660	MCF. Synthetic.
23	246	64.4	76	16	R87680	Monocyte chemotact
24	246	64.4	76	16	R87677	(3-Ala) MCP-1. Ho
25	246	64.4	76	17	W09374	Monocyte chemotact
26	246	64.4	76	18	W11311	Mature human monoc
27	246	64.4	76	19	W40175	Macrophage chemot
28	246	64.4	76	21	B12818	Human glioma cell
29	246	64.4	76	21	Y69030	Amino acid sequenc
30	246	64.4	77	16	R86859	Mature MCP-1. Hom
31	246	64.4	99	10	P95387	Human monocyte che
32	246	64.4	99	13	R28663	MCF. Synthetic.
33	246	64.4	99	16	R73914	Human monocyte che
34	246	64.4	99	16	R70800	Chemottractant pr
35	246	64.4	99	19	W40174	Macrophage chemot
36	246	64.4	99	20	Y48391	Human prostate can
37	246	64.4	99	20	Y26176	Monocyte chemotatr
38	246	64.4	99	21	B15785	Human chemokine MC
39	246	64.4	325	21	Y69049	A chemokine recept
40	246	64.4	327	21	Y69050	A chemokine recept
41	246	64.4	332	21	Y69051	A chemokine recept
42	242	63.4	99	11	R06398	Human MCF precurs
43	239	62.6	68	18	W13597	Monocyte chemotatr
44	239	62.6	69	16	R87678	des(2-8) MCP-1. H
45	238	62.3	76	16	R87676	(24-Arg) MCP-1. H

ALIGNMENTS

RESULT 1	
Y07234	Y07234 standard; protein; 71 AA.
AC	Y07234:
XX	
XX	06-JUL-1999 (first entry)
DT	
XX	
DE	Truncated monocyte chemotactic protein 2 (6-76).
XX	
KW	Wild type; C-C chemokine; monocyte chemotactic protein 2; MCP2; HIV;
KW	regulated on activation; normal T-cell expressed and secreted; RANTES;
KW	truncation; antagonist; medicaments; diagnosis; inflammation; infection;
KW	tumour; angiogenesis; hematopoiesis; autoimmune disease; atherosclerosis;
KW	pulmonary disease; skin disorder.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PN	EP906954-A1.
PD	07-APR-1999.
PF	29-SEP-1997; 97EP-0116863.
PR	29-SEP-1997; 97EP-0116863.
XX	
PA	(ISTF) ARS APPLIED RES SYSTEMS HOLDING NV.
XX	
PI	Proost P, Struyf S, Van Damme J;
XX	
DR	WPI, 1999-207108/18.
XX	
PT	New amino-terminally truncated C-C chemokines have antagonistic

PT activity for treatment of immune, inflammatory and infectious diseases

XX Claim 4; Fig 1; 29pp; English.

XX This sequence represents a truncated C-C chemokine monocyte chemotactic protein 2 (MCP2) containing amino acids 6-76 of the mature protein.

CC The invention relates the generation of amino-terminal truncated C-C chemokines, having chemokine antagonistic activity. The new chemokines are useful as medicaments, for diagnosis and/or treatment of diseases which require antagonistic activity of a chemokine e.g. inflammatory diseases, HIV infection, tumours, and angiogenesis- and hematopoiesis-related diseases, including auto-immune diseases, atherosclerosis, pulmonary diseases and skin disorders.

CC Sequence 71 AA:

SO

Query Match 100.0%; Score 382; DB 20; Length 71;
 Local Similarity 100.0%; Pred. No. 1.2e-38;
 Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIPTCCFVNIRKIPRIORLESYRTNTNOCPEKAVIFKTRKKEVCADPKRWRDMSK 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1 SIPTCCFVNIRKIPRIORLESYRTNTNOCPEKAVIFKTRKKEVCADPKRWRDMSK 60

OY 61 HLDQIFQNLKP 71
 ||||||||||||
 Db 61 hldqifqnlkp 71

RESULT 2
 Y07238
 ID Y07238 standard; protein; 71 AA.

XX AC Y07238;
 XX 06-JUL-1999 (first entry)

DE Truncated monocyte chemotactic protein 2 (6-76).

XX Wild type: C-C chemokine; monocyte chemotactic protein 2; MCP2; HIV; regulated on activation normal T-cell expressed and secreted; RANTES; truncation; antagonist; medicaments; diagnosis; inflammation; infection; tumour; angiogenesis; hematopoiesis; autoimmune disease; atherosclerosis; pulmonary disease; skin disorder.

OS Homo sapiens.
 OE Synthetic.

XX EP905241-A1.
 PN 31-MAR-1999.

XX 10-MAR-1998; 98EP-0104216.

XX 19-DEC-1997; 97EP-0122471.
 PR 29-SEP-1997; 97EP-0116863.

XX (ISNF) ARS APPLIED RES SYSTEMS HOLDING NV.

XX Proost P, Struyf S, Van Damme J;
 PI Proost P, Struyf S, Van Damme J;
 DR WPI; 1999-206774/18.

PT New amino-terminally truncated C-C chemokines have antagonistic activity for treatment of immune, inflammatory and infectious diseases

XX Claim 4; Fig 1; 29pp; English.

CC This sequence represents a truncated C-C chemokine monocyte chemotactic protein 2 (MCP2) containing amino acids 6-76 of the mature protein.

CC The invention relates the generation of amino-terminal truncated C-C chemokines, having chemokine antagonistic activity. The new chemokines are useful as medicaments, for diagnosis and/or treatment of diseases which require antagonistic activity of a chemokine e.g. inflammatory diseases, HIV infection, tumours, and angiogenesis- and hematopoiesis-related diseases, including auto-immune diseases, atherosclerosis, pulmonary diseases and skin disorders.

CC Sequence 71 AA:

SO

Query Match 100.0%; Score 382; DB 20; Length 71;
 Best Local Similarity 100.0%; Pred. No. 1.2e-38;
 Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIPTCCFVNIRKIPRIORLESYRTNTNOCPEKAVIFKTRKKEVCADPKRWRDMSK 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1 SIPTCCFVNIRKIPRIORLESYRTNTNOCPEKAVIFKTRKKEVCADPKRWRDMSK 60

OY 61 HLDQIFQNLKP 71
 ||||||||||||
 Db 61 hldqifqnlkp 71

RESULT 3
 Y69031
 ID Y69031 standard; protein; 76 AA.

XX AC Y69031;
 XX 30-MAY-2000 (first entry)

DE Amino acid sequence of chemokine receptor ligand MCP-2.

XX Chemokine receptor; ligand; inflammatory response; immune effector cell; secondary tissue damage; central nervous system injury; MCP-2;
 KW CNS inflammatory disease; neurodegenerative disorder; heart disease;
 KW inflammatory eye disease; inflammatory bowel disease;
 KW inflammatory joint disease; inflammatory kidney; renal disease;
 KW inflammatory lung disease; inflammatory nasal disease;
 KW inflammatory thyroid disease; thyroiditis; cytokine-regulated cancer.

OS Homo sapiens.
 XX WO200004926-A2.
 PN 03-FEB-2000.

XX 21-JUL-1999; 99NO-CA00659.
 PR 22-JUL-1998; 98US-0120523.

XX (OSPREY) OSPREY PHARM LTD.
 PA McDonald JR, Coggin PJ;
 PI McDonald JR, Coggin PJ;
 DR WPI; 2000-182542/16.

PT A new therapeutic agent comprising a conjugate for treating secondary tissue damage and other disease conditions like Alzheimer's disease, stroke, Parkinson's disease and atherosclerosis

XX Disclosure; Page 60; 204pp; English.

CC The present sequence represents a chemokine receptor ligand. The present ligand can be incorporated into the conjugates of the invention. The specification describes a conjugate, comprising a targeted agent and a chemokine receptor ligand. The conjugate binds to a chemokine receptor resulting in internalisation of the targeted agent in cells bearing the receptor. The conjugates are used for formulating a medicament or for treating disorders associated with inflammatory responses resulting from activation, proliferation and migration of immune effector cells. The disorders or disease states comprise secondary tissue damage such as

CC central nervous system (CNS) injury, CNS inflammatory diseases,
 CC neurodegenerative disorders, heart disease, inflammatory eye diseases,
 CC inflammatory bowel diseases, inflammatory joint diseases, inflammatory
 CC kidney or renal diseases, inflammatory lung diseases, inflammatory
 CC nasal diseases, inflammatory thyroid disease such as thyroiditis, or
 CC cytokine-regulated cancers.

XX
 SQ Sequence 76 AA:

Query Match 100.0%; Score 382; DB 21; Length 76;
 Best Local Similarity 100.0%; Pred. No. 1.3e-38;
 Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIPTCCFVNIRKIPRIORLESYTRITNIOCPKEAVIFKTRKREVCADPKRWRVDSMK 60
 Db 6 sptlccfnvnrkriprioriesytritinigpkeavifktrkrevcadpkerrvrdsmk 65

OY 61 HLDQIFQNLKP 71
 66 hldqifqnlkp 76

RESULT 4

B15786
 ID B15786 standard; Protein; 77 AA.

AC B15786;

DT 17-JAN-2001 (first entry)

DE Human chemokine MCP-2 SEQ ID NO: 17.

XX
 DE Macrophage recruitment; chemokine derivative; MCP-1; osteoporosis;
 KW monocyte chemoattractant protein-1; inflammation; atherosclerosis; HIV;
 KW AIDS; stroke; psoriasis; autoimmune disease; hypertension; endotoxaemia;
 KW basophil-mediated disease; myocardial infarction; acute ischaemia;
 KW rheumatoid arthritis; contraception.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Misc-difference 47 /note="encoded by CAA"

PN WO200042071-A2.

PD 20-JUL-2000.

XX 12-JAN-2000; 2000WO-US00821.

PR 12-JAN-1999; 99US-0229071.

PR 17-MAR-1999; 99US-0271192.

PR 01-DEC-1999; 99US-0452406.

XX (NEOR-) NEORX CORP.

PI Grainger DJ, Tatalick LM;

DR WPI: 2000-499101/44.

DR N-PSDB; A74886.

XX New peptide 3, amide and heterocyclic compounds and saccharide
 PT conjugates used for inhibiting chemokine induced activity and for
 PT treating e.g. stroke, vascular diseases, autoimmune diseases and tumour
 PT growth.

XX Example 1; Page 134; 387pp; English.

XX The present invention concerns the identification of a number of
 CC chemokines which can be used to produce derivatives, agonists and
 CC antagonists which are then useful in disease treatment. The chemokines
 CC include sequences B15785-B15794, B15803-B15813 and B15831-B15848. These

CC chemokine derivatives can be used to treat diseases such as autoimmune
 CC diseases, atherosclerosis, osteoporosis, HIV infection and AIDS,
 CC psoriasis, inflammatory diseases, hypertension, basophil-mediated
 CC diseases, endotoxaemia, myocardial infarction, acute ischaemia and
 CC rheumatoid arthritis, and can be used to prevent strokes and as
 CC contraceptives. The coding sequences for the chemokines can be used in
 CC gene therapy for the same diseases, as well as in the production of
 CC animal models.

XX
 SQ Sequence 77 AA:

Query Match 100.0%; Score 382; DB 21; Length 77;
 Best Local Similarity 100.0%; Pred. No. 1.3e-38;
 Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIPTCCFVNIRKIPRIORLESYTRITNIOCPKEAVIFKTRKREVCADPKRWRVDSMK 60
 Db 7 sptlccfnvnrkriprioriesytritinigpkeavifktrkrevcadpkerrvrdsmk 66

OY 61 HLDQIFQNLKP 71
 67 hldqifqnlkp 77

RESULT 5

Y05300
 ID Y05300 standard; protein; 99 AA.

AC Y05300;

DT 25-JUN-1999 (first entry)

DE C-C chemokine, MCP2.

XX C-C chemokine; MCP2; chemokine antagonist; inflammatory disease;
 KW HIV infection; tumour; angiogenesis-related disease; autoimmune disease;
 KW haematopoiesis-related disease; CD26/DPF IV; immune disease; diagnosis;
 KW atherosclerosis; pulmonary disease; skin disorder; therapy.

XX Homo sapiens.

XX EP905240-A1.

PN 31-MAR-1999.

PD 19-DEC-1997; 97EP-0122471.

XX 29-SEP-1997; 97EP-0116863.

XX (1STF) ARS APPLIED RES SYSTEMS HOLDING NV.

PI Proost P, Struyf S, Van Damme J;

DR WPI: 1999-216695/19.

XX New amino-terminally truncated C-C chemokines have antagonistic
 PT activity, for treatment of immune, inflammatory and infectious
 PT diseases

XX Claim 4; Fig 1; 30pp; English.

XX This sequence represents the C-C chemokine MCP2. The invention relates
 CC to amino-terminally truncated C-C chemokines, having chemokine
 CC antagonistic activity. The truncated chemokines are specifically residues
 CC 26 to 91 of the RANTES sequence (see Y05299) or residues 29 to 99 of
 CC the MCP2 sequence (this sequence). The new chemokines are useful as
 CC medicaments, for diagnosis and/or treatment of diseases which require
 CC antagonistic activity of a chemokine e.g. inflammatory diseases, HIV
 CC infection, tumours, and angiogenesis- and haematopoiesis-related
 CC diseases. The invention also relates to the use of CD26/DPF IV for
 CC treatment of inflammatory, immune and infectious diseases, including
 CC autoimmune diseases, atherosclerosis, pulmonary diseases and skin

CC disorders.
XX
SQ Sequence 99 AA;

Query Match 100.0%; Score 382; DB 20; Length 99;
Best Local Similarity 100.0%; Pred. No. 1.7e-38;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIPTCCFNVINRKIPQRLSYRTITNIOCPKEAVIFKTRKRGKVCADPKERWRDSMK 60
DB 29 sipitccfnvinrkikipqrlsyrtitnigcpkeavifktrkrgkvcadpkervrdsnk 88
OY 61 HLDQIFQNLKP 71
DB 89 hldqifqnlkp 99

RESULT 6
Y07237
I07233 standard; protein; 99 AA.

AC Y07233;

DF 06-JUL-1999 (first entry)

DE Wild type monocyte chemotactic protein 2.

XX Wild type; C-C chemokine; monocyte chemotactic protein 2; MCP2; HIV;
KW regulated on activation normal T-cell expressed and secreted; RANTES;
KW truncation; antagonist; medicaments; diagnosis; inflammation; infection;
KW tumour; angiogenesis; hematopoiesis; autoimmune disease; atherosclerosis;
KW pulmonary disease; skin disorder.

XX Homo sapiens.

PN EP906954-A1.

PD 07-APR-1999.

PF 29-SEP-1997; 97EP-0116863.

PR 29-SEP-1997; 97EP-0116863.

PA (ISTF) ARS APPLIED RES SYSTEMS HOLDING NV.

PI Proost P, Struyf S, Van Damme J;

DB WPI; 1999-207108/18.

XX New amino-terminally truncated C-C chemokines have antagonistic
PT activity for treatment of immune, inflammatory and infectious
PT diseases
PS Disclosure; Fig 1; 29pp; English.

XX This sequence represents the wild type C-C chemokine monocyte chemotactic
CC protein 2 (MCP2). The invention relates the generation of amino-terminal
CC truncated C-C chemokines, having chemokine antagonistic activity. The
CC new chemokines are useful as medicaments, for diagnosis and/or treatment
CC of diseases which require antagonistic activity of a chemokine e.g.
CC inflammatory diseases, HIV infection, tumours, and angiogenesis- and
CC hematopoiesis-related diseases, including auto-immune diseases,
CC atherosclerosis, pulmonary diseases and skin disorders.

XX Sequence 99 AA;

Query Match 100.0%; Score 382; DB 20; Length 99;
Best Local Similarity 100.0%; Pred. No. 1.7e-38;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIPTCCFNVINRKIPQRLSYRTITNIOCPKEAVIFKTRKRGKVCADPKERWRDSMK 60

DB 29 sipitccfnvinrkikipqrlsyrtitnigcpkeavifktrkrgkvcadpkervrdsnk 88

OY 61 HLDQIFQNLKP 71
DB 89 hldqifqnlkp 99

RESULT 7

Y07237
I07237 standard; protein; 99 AA.

AC Y07237;

DF 06-JUL-1999 (first entry)

DE Wild type monocyte chemotactic protein 2.

XX Wild type; C-C chemokine; monocyte chemotactic protein 2; MCP2; HIV;
KW regulated on activation normal T-cell expressed and secreted; RANTES;
KW truncation; antagonist; medicaments; diagnosis; inflammation; infection;
KW tumour; angiogenesis; hematopoiesis; autoimmune disease; atherosclerosis;
KW pulmonary disease; skin disorder.

XX Homo sapiens.

PN EP905241-A1.

PD 31-MAR-1999.

PF 10-MAR-1998; 98EP-0104216.

PR 19-DEC-1997; 97EP-0122471.

PA (ISTF) ARS APPLIED RES SYSTEMS HOLDING NV.

PI Proost P, Struyf S, Van Damme J;

DB WPI; 1999-206774/18.

XX New amino-terminally truncated C-C chemokines have antagonistic
PT activity for treatment of immune, inflammatory and infectious
PT diseases
PS Disclosure; Fig 1; 36pp; English.

XX This sequence represents the wild type C-C chemokine monocyte chemotactic
CC protein 2 (MCP2). The invention relates the generation of amino-terminal
CC truncated C-C chemokines, having chemokine antagonistic activity. The
CC new chemokines are useful as medicaments, for diagnosis and/or treatment
CC of diseases which require antagonistic activity of a chemokine e.g.
CC inflammatory diseases, HIV infection, tumours, and angiogenesis- and
CC hematopoiesis-related diseases, including auto-immune diseases,
CC atherosclerosis, pulmonary diseases and skin disorders.

XX Sequence 99 AA;

Query Match 100.0%; Score 382; DB 20; Length 99;
Best Local Similarity 100.0%; Pred. No. 1.7e-38;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIPTCCFNVINRKIPQRLSYRTITNIOCPKEAVIFKTRKRGKVCADPKERWRDSMK 60
DB 29 sipitccfnvinrkikipqrlsyrtitnigcpkeavifktrkrgkvcadpkervrdsnk 88
OY 61 HLDQIFQNLKP 71
DB 89 hldqifqnlkp 99

RESULT 8

W42072
ID W42072 standard; Protein; 109 AA.
XX
AC W42072;
XX
DT 09-JUN-1998 (first entry)
XX
DE Human MC proprotein.
XX
KW Human monocyte chemotactic proprotein; MCPP. Incyte clone; allergy;
KW macrophage; diagnostic assay; body fluid; lung; biopsy;
KW autoimmune disease; AIDS; asthma; rheumatoid arthritis; NIDDM;
KW breast cancer; bladder.
XX
OS Homo sapiens.
XX
PN W09802459-A1.
XX
PD 22-JAN-1998.
XX
F 15-JUL-1997; 97WO-US12349.
XX
PR 15-JUL-1996; 96US-0683655.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Au-Young J, Coleman R, Hillman JL;
XX
DR WPI: 1998-110529/10.
DR N-PSDB: V09218.
XX
PT New human monocyte chemotactic proprotein - has homology to CC
PT chemokine(s) useful for identifying agent for treating auto-immune
PT diseases or allergic responses
XX
PS Claim 1: Pages 38-39; 53pp; English.
XX
CC The is a human monocyte chemotactic proprotein sequence. Its cDNA was
CC first identified in Incyte clone 965517 from a breast cDNA library.
CC Antisense nucleotides can be used to control human MCPP expression
CC especially where it may lead to inappropriate monocyte or macrophage
CC activity causing damage associated with allergic responses to organs
CC such as the lungs. Antisense nucleotides and MCPP cDNA may be used
CC in diagnostic assays of body fluids or biopsied tissues to detect
CC expression levels of MCPP. MCPP cDNA may also be useful for
CC treatment of disorders such as asthma, rheumatoid arthritis, NIDDM
CC or cancer of the breast or bladder. Human MCPP protein can be used to
CC identify agonists, antagonists or inhibitors to modulate the activity of
CC MCPP in allergic responses or autoimmune diseases such as AIDS.
XX
SQ Sequence 109 AA;
XX
Query Match 100.0%; Score 382; DB 19; Length 109;
Best Local Similarity 100.0%; Pred. No. 1,9e-38;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 SIPITCCFNVINRKIPIDRIESTYRTINIOCPKEAVIFKTKRGEVCADPKERWVDSMK 60
DB 39 stptctcfnvinrkpikpdlqrlsytirltnigcpkcaavifktkygkvcadpketwvdsnk 98
OY 61 HLDQIFONLKP 71
DB 99 hldqifgnlkp 109

RESULT 9
W26655
ID W26655 standard; Protein; 109 AA.
XX
AC W26655;
XX
DT 16-FEB-1998 (first entry)
XX

XX
DE Human beta-chemokine H1305 (MCP-2).
XX
KW H1305; MCP-2; chemokine; human; chemoattractant; chemotaxis;
KW virus infection; HIV; therapy; wound healing; tumour; antibody.
XX
OS Homo sapiens.
XX
PN W09725427-A1.
XX
PD 17-JUL-1997.
XX
F 10-JAN-1997; 97WO-US00379.
XX
PR 12-JAN-1996; 96US-0586395.
XX
PA (GEMV) GENETICS INST INC.
XX
PI Lavallie ER, McCoy JM, Racie LA;
XX
DR WPI: 1997-372866/34.
DR N-PSDB: T91023.
XX
PT New human beta-chemokine, H1305 and corresponding DNA - used in the
PT treatment of viral infection, e.g. HIV, and in wound healing
XX
PS Claim 1; Page 12-13; 21pp; English.
XX
CC This protein comprises human beta-chemokine H1305, also known as
CC MCP-2. Its sequence was deduced from a claimed cDNA clone (see
CC T91023) isolated from a human peripheral blood mononuclear cell
CC cDNA library. Also claimed are: (1) a host cell, preferably
CC mammalian, transformed with a H1306 polynucleotide operably linked
CC to an expression control sequence; (2) a recombinantly produced
CC H1305 protein; and (3) a composition comprising an antibody which
CC specifically reacts with the H1305 protein. The H1305 protein
CC may be used in a composition for the treatment of a mammalian
CC subject (claimed). It is thought to have chemokine activities and
CC may therefore have an effect on chemotaxis or migration of blood
CC cells. It may be useful for inhibiting viral replication,
CC including replication of HIV, and may also be used for treatment of
CC wounds and to raise monoclonal and polyclonal antibodies which
CC specifically react with H1305. Such antibodies may be used for
CC therapy of certain tumours as they are capable of blocking the
CC ligand binding of the H1305 protein or may promote clearance of
CC the protein from the patient.
XX
SQ Sequence 109 AA;
XX
Query Match 99.0%; Score 378; DB 18; Length 109;
Best Local Similarity 98.6%; Pred. No. 5.8e-38;
Matches 70; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 1 SIPITCCFNVINRKIPIDRIESTYRTINIOCPKEAVIFKTKRGEVCADPKERWVDSMK 60
DB 39 stptctcfnvinrkpikpdlqrlsytirltnigcpkcaavifktkygkvcadpketwvdsnk 98
OY 61 HLDQIFONLKP 71
DB 99 hldqifgnlkp 109

RESULT 10
Y14223
ID Y14223 standard; peptide; 77 AA.
XX
AC Y14223;
XX
DT 29-JUL-1999 (first entry)
XX
DE Chemokine hMCP2.
XX

KW Chemokine; immune response; monocyte chemoattractant protein-1; MCP-1;
 KW chemokine-induced activity; inflammatory response; vascular indication;
 KW haematopoietic cell-associated activity; tumour; coronary artery disease;
 KW myocardial infarction; unstable angina pectoris; atherosclerosis; asthma;
 KW vasculitis; lentiviral infection; low bone mineral density; suppressor;
 KW parasitic infection; autoimmune disease; psoriasis; wound healing;
 KW organ transplant rejection; rheumatoid arthritis; allergy; therapy;
 KW arachidonic acid pathway.

OS Homo sapiens.

PN MO9912968-A2.

PD 18-MAR-1999.

PF 11-SEP-1998; 98WO-US19052.

PR 11-SEP-1997; 97US-0927939.

PS (NEOR-) NEORX CORP.

PI Grainger DJ, Kanaly ST, Tatalick LM;

DR WPI: 1999-347124/29.

XX New chemokine peptides and mimetics

XX Example 1; Page 128; 208pp; English.

XX This sequence represents the chemokine hMCP-2.

CC The invention relates to chemokine peptides and mimetics, particularly
 CC derived from monocyte chemoattractant protein-1 (MCP-1). The chemokine
 CC peptides and variants and derivatives can inhibit or reduce or increase,
 CC or enhance chemokine-induced activity. They can be used for increasing or
 CC enhancing an inflammatory response, an immune response or haematopoietic
 CC cell-associated activity at a tumour site. They can also be used for
 CC preventing or inhibiting an indication associated with haematopoietic
 CC cell recruitment or histamine release from basophils or mast cells. They
 CC can also be used to modulate the chemokine-induced activity of
 CC haematopoietic cells at a preselected physiological site, to treat a
 CC vascular indication, e.g. coronary artery disease, myocardial infarction,
 CC unstable angina pectoris, atherosclerosis, or vasculitis, lentiviral
 CC infection or replication (e.g. HIV), low bone mineral density, a
 CC parasitic infection in a vertebrate animal (e.g. malaria), an autoimmune
 CC disease, to suppress tumour growth in a vertebrate animal, to prevent or
 CC treat asthma, organ transplant rejection, rheumatoid arthritis or
 CC allergy. They can also be used to inhibit a product or intermediate in
 CC the arachidonic acid pathway and where leukotriene, thromboxane and/or
 CC prostaglandin are inhibited and to prevent or inhibit an indication
 CC associated with elevated TNF-alpha.

XX Sequence 77 AA:

Query Match 94.0%; Score 359; DB 20; Length 77;
 Best Local Similarity 95.8%; Pred. No. 7.4e-36;
 Matches 68; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 SIPTCCFNVNKKIPQRLSEYTRITNIQCPKEAVIFKTRGKEVCADPKERWVDSMK 60
 DB 7 sIptccpvnlnrkkipqrlseYtrItNiqcpkeavIfktrgkEvcadpkerwvdsnk 66

QY 61 HLDQIFQNLKP 71
 DB 67 hldqIfgnlKp 77

RESULT 11
 ID R70804 standard; Protein: 72 AA.
 XX R70804;
 AC

XX 29-AUG-1995 (first entry)

DE Chemottractant MCP-2.

XX Chemottractant; MCP-2; heparanase; heparin; heparan sulfate;

XX arthritis; restenosis; cancer; wound healing.

OS Homo sapiens.

PN MO9504158-A.

PD 09-FEB-1995.

PF 26-JUL-1994; 94WO-US08207.

PR 29-JUL-1993; 93US-0099866.

PR 13-OCT-1993; 93US-0136117.

PS (UPJO) UPJOHN CO.

PI Hoogwerf AJ, Ledbetter SR;

DR WPI: 1995-082239/11.

XX Screening for cpds. with anti-heparanase activity - by detecting

XX inhibition of heparin or heparan sulphate degradation,

XX potentially useful for treating arthritis, restenosis, cancer.

XX Claim 13; Page 53; 60pp; English.

XX Purified heparanases, prepared under reducing conditions and

XX activated with transglutaminase, are given in R70786-804. Most

XX are prepared by reverse transcription of mRNA from activated human

XX leukocytes, then cloning of the cDNA into pVL1392 baculovirus

XX vector, and expression in Sf9 cells in the presence of reduced

XX glutathione and dithiothreitol.

XX Sequence 72 AA:

Query Match 90.1%; Score 344; DB 16; Length 72;
 Best Local Similarity 94.4%; Pred. No. 4.3e-34;
 Matches 67; Conservative 0; Mismatches 2; Indels 2; Gaps 1;

QY 1 SIPTCCFNVNKKIPQRLSEYTRITNIQCPKEAVIFKTRGKEVCADPKERWVDSMK 60
 DB 4 sIptccpvnlnrkkipqrlseYtrItNiqcpkeavIfktrgkEvcadpkerwvdsnk 61

QY 61 HLDQIFQNLKP 71
 DB 62 hldqIfgnlKp 72

RESULT 12

ID Y69023 standard; Protein: 74 AA.

XX Y69023;

XX 30-MAY-2000 (first entry)

XX Amino acid sequence of chemokine receptor ligand eotaxin.

XX Chemokine receptor; ligand; inflammatory response; immune effector cell;

XX secondary tissue damage; central nervous system injury; eotaxin;

XX CNS inflammatory disease; neurodegenerative disorder; heart disease;

XX inflammatory eye disease; inflammatory bowel disease;

XX inflammatory joint disease; inflammatory kidney; renal disease;

XX inflammatory lung disease; inflammatory nasal disease;

XX inflammatory thyroid disease; thyroiditis; cytokine-regulated cancer.

XX Homo sapiens.

OS

XX XX W0200004926-A2.
 PN XX
 PD XX 03-FEB-2000.
 XX XX
 PF 21-JUL-1999; 99WO-CA00659.
 XX XX
 PR 22-JUL-1998; 98US-0120523.
 XX XX
 PA (OSPR-) OSPREY PHARM LTD.
 XX XX
 PI McDonald JR, Coggin PJ;
 XX XX
 DR WPI; 2000-182542/16.
 XX XX
 PT A new therapeutic agent comprising a conjugate for treating secondary
 PT tissue damage and other disease conditions like Alzheimer's disease,
 PT stroke, Parkinson's disease and atherosclerosis
 XX XX
 PS Disclosure; Page 59; 204pp; English.
 CC The present sequence represents a chemokine receptor ligand. The present
 CC ligand can be incorporated into the conjugates of the invention. The
 CC specification describes a conjugate, comprising a targeted agent and a
 CC chemokine receptor ligand. The conjugate binds to a chemokine receptor
 CC resulting in internalisation of the targeted agent in cells bearing the
 CC receptor. The conjugates are used for formulating a medicament or for
 CC treating disorders associated with inflammatory responses resulting from
 CC activation, proliferation and migration of immune effector cells. The
 CC disorders or disease states comprise secondary tissue damage such as
 CC central nervous system (CNS) injury, CNS inflammatory diseases,
 CC neurodegenerative disorders, heart disease, inflammatory eye diseases,
 CC inflammatory bowel diseases, inflammatory joint diseases, inflammatory
 CC kidney or renal diseases, inflammatory lung diseases, inflammatory
 CC nasal diseases, inflammatory thyroid disease such as thyroiditis, or
 CC cytokine-regulated cancers.
 CC XX
 SQ Sequence 74 AA;
 Query Match 69.9%; Score 267; DB 21; Length 74;
 Best Local Similarity 66.2%; Pred. No. 7.5e-25;
 Matches 47; Conservative 13; Mismatches 11; Indels 0; Gaps 0;
 OY 1 SIPTCCFNVNIRKIPRIORLESYTRITNIQCPKEAVIFKTKRKEVCADPKERWRDSMK 60
 DB 4 svptccfnlanrkiprilestysgkcpqkavifktkiakdcdpkkkvwgdsmk 63
 Q 61 HLDQIFQNLKP 71
 DB :||| ||
 64 yldqkspkp 74
 RESULT 13
 W00667
 ID W00667 standard; Protein; 97 AA.
 XX XX
 AC W00667;
 XX XX
 DT 02-MAY-1997 (first entry)
 XX XX
 DE Pancreas expressed chemokine-1.
 XX XX
 KW Pancreas-derived chemokine; PANEC-1; PANEC-2; diagnosis;
 KW inflammation; disease; cancer.
 XX XX
 OS Homo sapiens.
 XX XX
 PN W09625497-A1.
 XX XX
 PD 22-AUG-1996.
 XX XX
 PF 16-FEB-1996; 96WO-US02225.

XX XX 17-FEB-1995; 95US-0390740.
 PR XX
 PA (INCY-) INCYTE PHARM INC.
 XX XX
 PI Bandman O, Coleman R, Wilde CG;
 XX XX
 DR WPI; 1996-393398/39.
 XX XX
 DR N-PSDB; T33527.
 XX XX
 PT Nucleotide and protein sequences for human PANEC-1 and PANEC-2 -
 PT useful in diagnosis and therapy of pancreatic diseases
 XX XX
 PS Claim 8; Page 28-29; 43pp; English.
 CC The sequences given in W00667-68 represent pancreas-derived chemokines,
 CC PANEC-1 and PANEC-2. These chemokines are highly expressed and
 CC specifically expressed in the pancreas and may therefore be used in
 CC diagnostic assays based on chemokine production in cases of
 CC inflammation or disease affecting the pancreas. These assays allow
 CC the early and accurate diagnosis of pancreatic disorders, and can
 CC differentiate between invasive diseases and genetic syndromes.
 CC XX
 SQ Sequence 97 AA;
 Query Match 69.9%; Score 267; DB 17; Length 97;
 Best Local Similarity 66.2%; Pred. No. 1e-24;
 Matches 47; Conservative 13; Mismatches 11; Indels 0; Gaps 0;
 OY 1 SIPTCCFNVNIRKIPRIORLESYTRITNIQCPKEAVIFKTKRKEVCADPKERWRDSMK 60
 DB 27 svptccfnlanrkiprilestysgkcpqkavifktkiakdcdpkkkvwgdsmk 86
 QY 61 HLDQIFQNLKP 71
 DB :||| ||
 87 yldqkspkp 97
 RESULT 14
 W14990
 ID W14990 standard; Protein; 97 AA.
 XX XX
 AC W14990;
 XX XX
 DT 01-DEC-1997 (first entry)
 XX XX
 DE Human eosinocyte CC type chemokine eotaxin.
 XX XX
 KW Human; eosinocyte; CC type; chemokine; eotaxin; calcium; skin;
 KW small intestine; agonist; screening; antagonist; inflammation;
 KW antibody; diagnosis; assay; disorder; asthma; allergy; atopic.
 XX XX
 OS Homo sapiens.
 XX XX
 PN W09712914-A1.
 XX XX
 PD 10-APR-1997.
 XX XX
 PF 01-OCT-1996; 96WO-JP02851.
 XX XX
 PR 28-FEB-1996; 96GP-0041965.
 XX XX
 PR 05-OCT-1995; 95JP-0259067.
 XX XX
 PA (SHIO) SHIONOGI & CO LTD.
 XX XX
 PI Harada S, Kitaura M, Nakajima T;
 XX XX
 DR WPI; 1997-226168/20.
 XX XX
 DR N-PSDB; T62944.
 XX XX
 PT Human CC chemokine (eotaxin) active on eosinocytes - useful for
 PT screening for eotaxin (ant)agonist(s), e.g. for treating

PT Inflammation
 XX
 PS Claim 2; Pages 27-28; 45pp; Japanese.
 XX
 CC The present sequence is the human eosinocyte, CC type
 CC chemokine, eotaxin, which increases calcium flux in human
 CC eosinocytes and is a human analogue of guinea pig eotaxin. The
 CC eotaxin was derived from human small intestine, and is a specific
 CC agonist for human CC type chemokine receptor 3. It may be used to
 CC screen potential agonists and antagonists, which may be useful as
 CC anti-inflammatory. An anti-eotaxin antibody may be used in
 CC diagnostic assays for eotaxin, which is implicated in inflammatory
 CC disorders, e.g. asthma, other allergies and atopic skin
 CC inflammation.
 CC
 CC Sequence 97 AA:
 SQ
 Query Match 69.9%; Score 267; DB 18; Length 97;
 Local Similarity 66.2%; Pred. No. 1e-24;
 Matches 47; Conservative 13; Mismatches 11; Indels 0; Gaps 0;
 Oy 1 SIPITCCFVNIRKPIORLESYTRITNQCPKEAVIFKTRKGKVCADPKRWRDMSK 60
 Db 27 svptccfnlanrkplqrlsyrrltsqkcpqkavikfkakdicadpkkkwwgdsdk 86
 Oy 61 HLDQIFONLKP 71
 Db 87 yldqksptpkp 97
 RESULT 15
 W10099 standard; Protein; 97 AA.
 ID W10099
 AC W10099:
 DT 30-SEP-1997 (first entry)
 DE Human eotaxin.
 XX
 KW Human; eotaxin; eosinophil; chemottractant; stimulation;
 KW accumulation; attraction; chemotaxis; diagnosis; prevention;
 KW treatment; disease; inflammation; allergy; asthma; rhinitis;
 KW hypersensitivity; lung; pneumonia; Loeffler's; syndrome;
 KW interstitial; ILD; idiopathic pulmonary fibrosis;
 KW rheumatoid arthritis; systemic; lupus erythematosus; SLE;
 KW ankylosing spondylitis; sclerosis; Sjorgen's; polymyositis;
 KW dermatomyositis; bowel; anaphylaxis; drug; penicillin;
 KW cephalosporin; insect sting; Crohn's; ulcerative colitis;
 KW spondyloarthropathy; scleroderma; psoriasis; dermatosis;
 KW dermatitis; eczema; atopic; urticaria; necrotizing; cutaneous;
 KW vasculitis; myositis; fascitis; multiple sclerosis;
 KW myasthenia gravis; juvenile onset diabetes; glomerulonephritis;
 KW autoimmune; thyroiditis; Bechet's; graft; rejection;
 KW transplantation; allograft; graft versus host; cancer;
 KW leukocyte infiltration; reperfusion injury; atherosclerosis;
 KW haematologic malignancy; septic; endotoxic; shock;
 KW polymyositis; dermatomyositis; immunosuppression; immunodeficiency;
 KW AIDS; radiation therapy; chemotherapy; autoimmune; corticosteroid;
 KW infection.
 KM
 XX Homo sapiens.
 OS
 PN M09700960-A1.
 XX
 PD 09-JAN-1997.
 XX
 PF 21-JUN-1996; 96WO-US10723.
 XX
 PR 23-JUN-1995; 95US-0494093.
 XX
 PA (LEUK-) LEUKOSITE INC.

XX
 PI Mackay C, Newman W, Ponath PD, Qin S, Ringler DJ;
 XX WPI: 1997-087387/08.
 DR N-PSDB; T58777.
 DR
 XX
 PT New isolated human eotaxin gene - used to develop prods. for the
 PT diagnosis and treatment of e.g. inflammation, allergies, auto-immune
 PT disease, infections and tumours
 XX
 PS Claim 3; Pages 95-96; 130pp; English.
 XX
 CC The present sequence is human eotaxin (he), an eosinophil
 CC specific chemottractant capable of stimulating eosinophil
 CC accumulation and/or attracting eosinophils (including chemotaxis).
 CC It can be used to develop products for the diagnosis, prevention or
 CC treatment of he associated diseases or conditions. The products can
 CC be used to treat inflammatory or allergic diseases and conditions,
 CC including respiratory allergic diseases (e.g. asthma, allergic
 CC rhinitis, hypersensitivity lung diseases or pneumonitis,
 CC eosinophilic pneumonia, interstitial lung diseases (ILD) such as
 CC idiopathic pulmonary fibrosis or ILD associated with rheumatoid
 CC arthritis, systemic lupus erythematosus (SLE), ankylosing
 CC spondylitis, systemic sclerosis, Sjorgen's syndrome, polymyositis
 CC or dermatomyositis), systemic anaphylaxis or hypersensitivity
 CC responses, drug allergies (e.g. to penicillin and cephalosporins),
 CC insect sting allergies, inflammatory bowel diseases (e.g. Crohn's
 CC disease and ulcerative colitis), spondyloarthropathies,
 CC scleroderma, psoriasis and inflammatory dermatoses (e.g.
 CC dermatitis, eczema, atopic dermatitis, allergic contact dermatitis,
 CC urticaria and necrotizing, cutaneous and hypersensitivity
 CC vasculitis), eosinophilic myositis and fascitis, multiple
 CC sclerosis, SLE, myasthenia gravis, juvenile onset diabetes,
 CC glomerulonephritis, autoimmune thyroiditis, Bechet's disease, graft
 CC rejection (e.g. in transplantation) including allograft rejection or
 CC graft versus host disease and cancers with leukocyte infiltration
 CC of the skin or organs. The products can also be used to treat other
 CC diseases or conditions requiring the inhibition of undesirable
 CC inflammatory responses, including reperfusion injury,
 CC atherosclerosis, certain haematologic malignancies, cytokine
 CC induced toxicity (e.g. septic or endotoxic shock), polymyositis,
 CC dermatomyositis, immunosuppression (e.g. in individuals with
 CC immunodeficiency syndromes such as AIDS, undergoing radiation
 CC therapy, chemotherapy, therapy for autoimmune disease or other drug
 CC therapy, such as corticosteroid therapy, which causes
 CC immunosuppression), immunosuppression due to (e.g. congenital)
 CC deficiency (e.g. in eotaxin) or infectious diseases such as parasitic
 CC diseases.
 CC Degenerate primers based on the guinea pig eotaxin amino acid
 CC sequence were used for the reverse transcriptase polymerase chain
 CC reaction (RT-PCR) amplification of RNA isolated from inflamed,
 CC eosinophilic lung tissue obtained from Balb/c mice sensitised to
 CC ovalbumin. The amplification product was used as a probe to screen
 CC a human genomic library in vector EMBL3 SP6/77 to obtain the he
 CC gene.
 CC
 XX
 SQ Sequence 97 AA:
 Query Match 69.9%; Score 267; DB 18; Length 97;
 Best Local Similarity 66.2%; Pred. No. 1e-24;
 Matches 47; Conservative 13; Mismatches 11; Indels 0; Gaps 0;
 Oy 1 SIPITCCFVNIRKPIORLESYTRITNQCPKEAVIFKTRKGKVCADPKRWRDMSK 60
 Db 27 svptccfnlanrkplqrlsyrrltsqkcpqkavikfkakdicadpkkkwwgdsdk 86
 Oy 61 HLDQIFONLKP 71
 Db 87 yldqksptpkp 97

Tue May 29 14:33:55 2001

us-09-537-859-3.rag

Page 9

Search completed: May 29, 2001, 13:55:12
Job time: 128 sec



GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 29, 2001, 13:53:44 ; Search time 18.54 Seconds
(without alignments)
73.569 Million cell updates/sec

Title: US-09-537-859-3

Perfect score: 382
Sequence: 1 SLPITCCFENVIRKIPIDRL.....ENWVDSKHKLDIFQNLKP 71

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 185757 seqs, 19210857 residues

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

Issued_Patents_AA:*
1: /cgn2_6/ptodata/2/1aa/5A.COMB.pep.*
2: /cgn2_6/ptodata/2/1aa/5B.COMB.pep.*
3: /cgn2_6/ptodata/2/1aa/6A.COMB.pep.*
4: /cgn2_6/ptodata/2/1aa/6B.COMB.pep.*
5: /cgn2_6/ptodata/2/1aa/PTUS.COMB.pep.*
6: /cgn2_6/ptodata/2/1aa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	382	100.0	74	2	US-08-615-232A-6
2	382	100.0	74	3	US-08-470-323-6
3	382	100.0	76	1	US-08-480-449-20
4	382	100.0	76	2	US-08-716-188-3
5	382	100.0	76	2	US-08-660-542-20
6	382	100.0	77	1	US-08-347-492B-9
7	382	100.0	77	2	US-08-421-144A-6
8	382	100.0	77	2	US-08-798-143-9
9	267	69.9	74	4	US-08-613-822-20
10	246	64.4	76	1	US-07-956-862A-1
11	246	64.4	76	1	US-08-250-958-1
12	246	64.4	76	1	US-08-235-659-1
13	246	64.4	76	2	US-08-716-188-2
14	246	64.4	76	2	US-08-615-232A-5
15	246	64.4	76	3	US-08-470-323-5
16	246	64.4	78	1	US-08-330-163-12
17	246	64.4	78	1	US-08-482-111-12
18	246	64.4	78	5	PCT-US95-00605-1
19	246	64.4	99	1	US-08-127-499A-35
20	246	64.4	99	1	US-08-482-847-35
21	246	64.4	99	1	US-08-347-492B-8
22	246	64.4	99	1	US-08-480-449-19
23	246	64.4	99	2	US-08-479-126B-5
24	246	64.4	99	2	US-08-421-144A-5
25	246	64.4	99	2	US-08-726-830A-5
26	246	64.4	99	2	US-08-660-542-19
27	246	64.4	99	2	US-08-798-143-8

28	246	64.4	99	3	US-07-927-391-24	Sequence 24, Appl
29	246	64.4	99	3	US-08-995-156A-5	Sequence 5, Appl
30	246	64.4	99	3	US-09-044-856A-5	Sequence 5, Appl
31	246	64.4	99	3	US-09-044-855A-5	Sequence 5, Appl
32	246	64.4	99	5	PCT-US96-10087-5	Sequence 5, Appl
33	246	64.4	99	6	5212073-2	Patent No. 5212073
34	233	61.0	76	4	US-08-613-822-19	Sequence 19, Appl
35	233	61.0	99	1	US-08-480-449-18	Sequence 18, Appl
36	233	61.0	99	2	US-08-660-542-18	Sequence 18, Appl
37	233	61.0	99	4	US-08-613-822-18	Sequence 18, Appl
38	233	61.0	109	2	US-08-421-144A-7	Sequence 7, Appl
39	233	61.0	109	3	US-07-927-391-16	Sequence 16, Appl
40	232	60.7	76	2	US-08-716-188-4	Sequence 4, Appl
41	227	59.4	70	2	US-08-615-232A-7	Sequence 7, Appl
42	219	57.3	73	2	US-08-615-232A-2	Sequence 2, Appl
43	219	57.3	73	3	US-08-470-323-2	Sequence 2, Appl
44	218	57.1	86	2	US-08-421-144A-9	Sequence 9, Appl
45	215.5	56.4	98	4	US-08-613-822-4	Sequence 4, Appl

ALIGNMENTS

RESULT 1
US-08-615-232A-6
; Sequence 6, Application US/08615232A
; Patent No. 5993814

GENERAL INFORMATION:

APPLICANT: WILLIAMS, TIMOTHY J.

APPLICANT: JOSE, PETER J.

APPLICANT: GRIFFITHS-JOHNSON, DAVID A.

APPLICANT: HSUAN, JOHN J.

TITLE OF INVENTION: CHEMOTACTIC CYTOKINE

NUMBER OF SEQUENCES: 11

CORRESPONDENCE ADDRESS:

ADDRESSEE: NIXON & VANDERHYTE P.C.

STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR

CITY: ARLINGTON

STATE: VIRGINIA

COUNTRY: U.S.A.

ZIP: 22201-4714

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/615,232A

FILING DATE: 13-AUG-1996

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: GB 9318984

FILING DATE: 14-SEP-1993

APPLICATION NUMBER: GB 9408602

FILING DATE: 29-APR-1994

ATTORNEY/AGENT INFORMATION:

NAME: WILSON, MARY J.

REGISTRATION NUMBER: 32,955

REFERENCE/DOCKET NUMBER: 550-32

TELECOMMUNICATION INFORMATION:

TELEPHONE: (703) 816-4000

TELEFAX: (703) 816-4100

INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:

LENGTH: 74 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-615-232A-6

Query Match

100.0%; Score 382; DB 2; Length 74;

Best Local Similarity 100.0%; Pred. No. 2.3e-43;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIIPTCCFVNIKKIPRIORLESTYRTITNIOCPKEAVIFKTKRGKVCADPKERWVDSMK 60
|||||
DB 4 SIIPTCCFVNIKKIPRIORLESTYRTITNIOCPKEAVIFKTKRGKVCADPKERWVDSMK 63

OY 61 HLDQIFONLKP 71
|||||
DB 64 HLDQIFONLKP 74

RESULT 2
US-08-470-323-6
Sequence 6, Application US/08470323A
Patent No. 6031080

GENERAL INFORMATION:
APPLICANT: WILLIAMS, TIMOTHY J.
APPLICANT: JOSE, PETER J.

APPLICANT: GRIFFITHS-JOHNSON, DAVID A.
TITLE OF INVENTION: CHEMOTACTIC CYTOKINE
FILE REFERENCE: 550-33

CURRENT FILING DATE: 1995-06-06
EARLIER APPLICATION NUMBER: PCT/GB94/02006
EARLIER FILING DATE: 1994-09-14

EARLIER APPLICATION NUMBER: GB 9318984.3
EARLIER FILING DATE: 1993-09-14
EARLIER APPLICATION NUMBER: GB 94086902.2

EARLIER FILING DATE: 1994-04-29
NUMBER OF SEQ ID NOS: 11
SEQ ID NO 6

LENGTH: 74
TYPE: PRT
ORGANISM: human
US-08-470-323-6

Query Match 100.0%; Score 382; DB 3; Length 74;
Best Local Similarity 100.0%; Pred. No. 2.3e-43;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIIPTCCFVNIKKIPRIORLESTYRTITNIOCPKEAVIFKTKRGKVCADPKERWVDSMK 60
|||||
DB 4 SIIPTCCFVNIKKIPRIORLESTYRTITNIOCPKEAVIFKTKRGKVCADPKERWVDSMK 63

OY 61 HLDQIFONLKP 71
|||||
DB 64 HLDQIFONLKP 74

RESULT 3
US-08-480-449-20
Sequence 20, Application US/08480449
Patent No. 5688927

GENERAL INFORMATION:
APPLICANT: Godiska, Ronald
APPLICANT: Gray, Patrick W.

TITLE OF INVENTION: MACROPHAGE DERIVED CHEMOKINE
NUMBER OF SEQUENCES: 24
CORRESPONDENCE ADDRESS:

ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago

STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/480,449

FILING DATE:
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Gass, David A.

REGISTRATION NUMBER: 38,153
REFERENCE/DOCKET NUMBER: 27866/32779
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448

TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:

LENGTH: 76 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: peptide
FEATURE:
NAME/KEY: misc.feature
OTHER INFORMATION: "Hu MCP-2"

US-08-480-449-20

Query Match 100.0%; Score 382; DB 1; Length 76;
Best Local Similarity 100.0%; Pred. No. 2.4e-43;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIIPTCCFVNIKKIPRIORLESTYRTITNIOCPKEAVIFKTKRGKVCADPKERWVDSMK 60
|||||
DB 6 SIIPTCCFVNIKKIPRIORLESTYRTITNIOCPKEAVIFKTKRGKVCADPKERWVDSMK 65

OY 61 HLDQIFONLKP 71
|||||
DB 66 HLDQIFONLKP 76

RESULT 4
US-08-716-188-3
Sequence 3, Application US/08716188
Patent No. 5908829

GENERAL INFORMATION:
APPLICANT: KELLY, RODNEY W
TITLE OF INVENTION: USE OF MCP-1 FOR INDUCING RIPENING OF
TITLE OF INVENTION: THE CERVIX

NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD

CITY: ARLINGTON
STATE: VA
COUNTRY: USA

ZIP: 22201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/716,188

FILING DATE: 30-SEP-1996
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB95/00733

FILING DATE: 31-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9406463.1

FILING DATE: 31-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: SADOFF, B.J.
REGISTRATION NUMBER: 36,663
REFERENCE/DOCKET NUMBER: 117-219

TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-816-4091
TELEFAX: 703-816-4100
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 76 amino acids
TYPE: amino acid
STRANDEDNESS: linear
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-716-188-3

Query Match
Best Local Similarity 100.0%; Score 382; DB 2; Length 76;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIPTCCFNVINRKIPRIQRLSEYTRITNIQCPKEAVIFKTKRGKVCADPKERWRDSMK 60
|||||
D 6 SIPTCCFNVINRKIPRIQRLSEYTRITNIQCPKEAVIFKTKRGKVCADPKERWRDSMK 65
|||||

OY 61 HLDQIFQNLKP 71
|||||

Db 66 HLDQIFQNLKP 76

RESULT 5
US-08-660-542-20
Sequence 20, Application US/08660542
Patent No. 5932703
GENERAL INFORMATION:
APPLICANT: Godiska, Ronald
APPLICANT: Gray, Patrick W.
TITLE OF INVENTION: MACROPHAGE DERIVED CHEMOKINE AND CHEMOKINE
TITLE OF INVENTION: ANALOGS
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/660,542
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/558,658
FILING DATE: 16-NOV-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/479,620
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Gass, David A.
REGISTRATION NUMBER: 38,153
REFERENCE/DOCKET NUMBER: 27866/33318
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 76 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide

FEATURE:
NAME/KEY: misc feature
OTHER INFORMATION: "Hu MCP-2"
US-08-660-542-20

Query Match
Best Local Similarity 100.0%; Score 382; DB 2; Length 76;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIPTCCFNVINRKIPRIQRLSEYTRITNIQCPKEAVIFKTKRGKVCADPKERWRDSMK 60
|||||
D 6 SIPTCCFNVINRKIPRIQRLSEYTRITNIQCPKEAVIFKTKRGKVCADPKERWRDSMK 65
|||||

OY 61 HLDQIFQNLKP 71
|||||

Db 66 HLDQIFQNLKP 76

RESULT 6
US-08-347-492B-9
Sequence 9, Application US/08347492B
Patent No. 5602008
GENERAL INFORMATION:
APPLICANT: Wilde, Craig G.
APPLICANT: Bandman, Olga R.
APPLICANT: Sellhammer, Jeffrey J.
TITLE OF INVENTION: EXPRESSED CHEMOKINES, THEIR
TITLE OF INVENTION: PRODUCTION AND USES
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: U.S.
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/347,492B
FILING DATE: 29-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/303,241
FILING DATE: 07-SEP-1994
APPLICATION NUMBER: 08/320,011
FILING DATE: 05-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Luther, Barbara J
REGISTRATION NUMBER: 33,954
REFERENCE/DOCKET NUMBER: PF-0024
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-852-0195
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 77 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
LIBRARY: GENBANK
CLONE: GI 126829
US-08-347-492B-9

Query Match
Best Local Similarity 100.0%; Score 382; DB 1; Length 77;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SIPTCCFVNINRKIPQRLSEYTRITNIQCPKRAVIFKTKRGKVCADPKRRWRDSMK 60
|||||

Db 7 SIPTCCFVNINRKIPQRLSEYTRITNIQCPKRAVIFKTKRGKVCADPKRRWRDSMK 66

QY 61 HLDQIFONLKP 71
|||||

Db 67 HLDQIFONLKP 77

RESULT 7
US-08-421-144A-6

Sequence 6, Application US/08421144A
Patent No. 5874211

GENERAL INFORMATION:

APPLICANT: BANDMAN, OLGA

APPLICANT: COLEMAN, ROGER

APPLICANT: STUART, SUSAN G.

TITLE OF INVENTION: NEW CHEMOKINE EXPRESSED IN EOSINOPHILS

NUMBER OF SEQUENCES: 9

CORRESPONDENCE ADDRESS:

ADDRESSEE: INCYTE PHARMACEUTICALS, INC.

STREET: 3174 Porter Drive

CITY: Palo Alto

STATE: CA

COUNTRY: USA

ZIP: 94304

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: IBM PC compatible

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/421,144A

FILING DATE: 13-APR-1995

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Luther, Barbara J.

REGISTRATION NUMBER: 33954

REFERENCE/DOCKET NUMBER: PF-0031 US

TELECOMMUNICATION INFORMATION:

TELEPHONE: 415-855-0555

TELEFAX: 415-852-0195

INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:

LENGTH: 77 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: protein

US-08-421-144A-6

Query Match

Best Local Similarity 100.0%; Score 382; DB 2; Length 77;

Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SIPTCCFVNINRKIPQRLSEYTRITNIQCPKRAVIFKTKRGKVCADPKRRWRDSMK 60
|||||

Db 7 SIPTCCFVNINRKIPQRLSEYTRITNIQCPKRAVIFKTKRGKVCADPKRRWRDSMK 66

QY 61 HLDQIFONLKP 71
|||||

Db 67 HLDQIFONLKP 77

RESULT 8

US-08-798-143-9

Sequence 9, Application US/08798143

Patent No. 5936068

GENERAL INFORMATION:

APPLICANT: Wilde, Craig G.

APPLICANT: Hawkins, Phillip R.

APPLICANT: Bandman, Olga

APPLICANT: Sellhammer, Jeffrey J.

TITLE OF INVENTION: EXPRESSED CHEMOKINES, THEIR

TITLE OF INVENTION: PRODUCTION AND USES

NUMBER OF SEQUENCES: 12

CORRESPONDENCE ADDRESS:

ADDRESSEE: Incyte Pharmaceuticals, Inc.

STREET: 3174 Porter Drive

CITY: Palo Alto

STATE: CA

COUNTRY: U.S.

ZIP: 94304

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

OPERATING SYSTEM: IBM compatible

SOFTWARE: FASTSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/798,143

FILING DATE: 10-FEB-1997

CLASSIFICATION: 536

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/347,492

FILING DATE: 29-NOV-1994

APPLICATION NUMBER: 08/303,241

FILING DATE: 07-SEP-1994

APPLICATION NUMBER: 08/320,011

FILING DATE: 05-OCT-1994

ATTORNEY/AGENT INFORMATION:

NAME: Luther, Barbara J.

REGISTRATION NUMBER: 33,954

REFERENCE/DOCKET NUMBER: PF-0024

TELECOMMUNICATION INFORMATION:

TELEPHONE: 415-855-0555

TELEFAX: 415-852-0195

INFORMATION FOR SEQ ID NO: 9:

SEQUENCE CHARACTERISTICS:

LENGTH: 77 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

IMMEDIATE SOURCE:

LIBRARY: GENBANK

CLONE: GI 126829

US-08-798-143-9

Query Match

Best Local Similarity 100.0%; Score 382; DB 2; Length 77;

Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SIPTCCFVNINRKIPQRLSEYTRITNIQCPKRAVIFKTKRGKVCADPKRRWRDSMK 60
|||||

Db 7 SIPTCCFVNINRKIPQRLSEYTRITNIQCPKRAVIFKTKRGKVCADPKRRWRDSMK 66

QY 61 HLDQIFONLKP 71
|||||

Db 67 HLDQIFONLKP 77

RESULT 9

US-08-613-822-20

Sequence 20, Application US/08613822

Patent No. 6174995

GENERAL INFORMATION:

APPLICANT: Li, Haodong

TITLE OF INVENTION: Human Chemokine Polypeptides

NUMBER OF SEQUENCES: 20

CORRESPONDENCE ADDRESS:

ADDRESSEE: Human Genome Sciences, Inc.

STREET: 9410 Key West Avenue

MOLECULE TYPE: peptidic

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 29, 2001, 13:54:05 ; Search time 21.3 seconds
(without alignments)
229.076 Million cell updates/sec

Title: US-09-537-859-3

Perfect score: 382
Sequence: 1 SIPTCCFNVNKRKIPQRL.....ERWVDSMKHLDQIFQNLKP 71

Scoring table: BIOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 198801 seqs, 68722935 residues

number of hits satisfying chosen parameters: 198801

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: PIR 67:*

1: PIR1: *
2: PIR2: *
3: PIR3: *
4: PIR4: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	378	99.0	99	2	JC5295
2	273	71.5	99	2	JC2417
3	270	70.7	97	2	JC4912
4	246	64.4	99	2	A60299
5	237	62.0	99	2	JC2136
6	233	61.0	109	2	A54678
7	219	57.3	96	2	I48099
8	212	55.5	96	2	JC2478
9	210	55.0	72	2	A53984
10	208	54.5	99	1	A39296
11	208	54.5	99	2	JC2336
12	207	54.2	148	1	A30209
13	206	53.9	125	2	I46857
14	196	51.3	148	1	S07723
15	189.5	49.6	120	2	I48147
16	172.5	45.2	97	2	A48093
17	149.5	39.1	93	2	B35673
18	142.5	37.3	92	2	A30574
19	138.5	36.3	92	1	A31767
20	136.5	35.7	92	2	I46730
21	130.5	34.2	92	2	C30552
22	129	33.8	92	2	I52322
23	128	33.5	92	2	A32393
24	127.5	33.4	114	1	ETHHL
25	121.5	31.8	91	1	A28815
26	118.5	31.0	114	1	ETMSL
27	116.5	30.5	91	1	A46539
28	116	30.4	120	2	JE0177
29	113	29.6	96	2	A37236

30	110	28.8	92	2	S24236
31	104	27.2	50	2	C60407
32	96	25.1	116	2	I49555
33	85	22.3	101	2	S42496
34	85	22.3	101	2	I46997
35	85	22.3	103	2	A44253
36	85	22.3	103	2	A53096
37	79	20.7	95	2	JN0841
38	77	20.2	101	2	I46871
39	75	19.6	99	2	A37034
40	72	18.8	101	2	I48148
41	71.5	18.7	117	2	B44253
42	71.5	18.7	459	2	T44201
43	71.5	18.7	459	2	T44014
44	66	17.3	114	2	A55010
45	66	17.3	132	2	A57325

ALIGNMENTS

RESULT 1
JC5295
monocyte chemotactic protein-2 precursor - human
C:Species: Homo sapiens (man)
C>Date: 02-May-1997 #sequence_revision 18-Jul-1997 #text_change 20-Jun-2000
C:Accession: J05295
R:Van Collille, E.; Froyen, G.; Nomiya, H.; Miura, R.; Fiten, P.; Van Aelst, I.; Van Blochem, Biophys. Res. Commun. 231, 726-730, 1997
A>Title: Human monocyte chemotactic protein-2: cDNA cloning and regulated expression
A:Reference number: J05295; MUID:97224420
A:Accession: J05295
A:Molecule type: mRNA
A:Residues: 1-99 <YAN>
A:CROSS-references: GB:Y10802; NID:q1924937; PIDN:CA71760.1; PID:q1924938
A:Experimental source: bone marrow
A:Comment: This protein belongs to the beta-chemokine family which is one of the major and in tumor biology, and contribute to the trafficking and recruitment of the res C:Genetics:
A:Gene: MCP-2
C:Superfamily: macrophage inflammatory protein
F:1-23/Domain: signal sequence #status predicted <SIG>
F:24-99/Product: monocyte chemotactic protein-2 #status predicted <MAT>

Query Match 99.0%; Score 378; DB 2; Length 99;
Best Local Similarity 98.6%; Pred. No. 1.7e-36;
Matches 70; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 SIPTCCFNVNKRKIPQRLSESYRTITNQCPEAVIFKTKGKREVCADPKERWVDSMK 60
|||||
DB 29 SIPTCCFNVNKRKIPQRLSESYRTITNQCPEAVIFKTKGKREVCADPKERWVDSMK 88
|||||

OY 61 HLDQIFQNLKP 71
|||||
DB 89 HLDQIFQNLKP 99
|||||

RESULT 2
JC2417
monocyte chemotactant protein-2 precursor - pig
C:Species: Sus scrofa domestica (domestic pig)
C>Date: 24-Feb-1995 #sequence_revision 24-Feb-1995 #text_change 16-Jul-1999
C:Accession: J02417
R:Hosang, K.; Knoke, I.; Klaudiny, J.; Wempe, F.; Wuttke, W.; Scheit, K.H.
Biochem. Biophys. Res. Commun. 205, 148-153, 1994
A>Title: Porcine luteal cells express monocyte chemotactant protein-2 (MCP-2): Ana A:Reference number: J02417; MUID:95091716
A:Accession: J02417
A:Molecule type: mRNA
A:Residues: 1-99 <HOS>
A:CROSS-references: GB:248480; NID:g663718; PIDN:CAA8371.1; PID:g663719
A:Experimental source: corpus luteum

C:Superfamily: macrophage inflammatory protein
 F:1-23/Domain: signal sequence #status predicted <SIG>
 F:24-99/Product: monocyte chemoattractant protein-2 #status predicted <MAT>

Query Match 71.5%; Score 273; DB 2; Length 99;
 Best Local Similarity 70.4%; Pred. No. 2e-24;
 Matches 50; Conservative 10; Mismatches 11; Gaps 0;

OY 1 SIPTCCFNVIRKIPICQLESTRTITNIOCPKEAVIFKTRKGVCAADPKERWRDMSK 60
 ||||||| :||| :||||| ||| :||||| ||||||| :||| :|||
 DB 29 SIPTCCFNVIRKIPICQLESTRTITNIOCPKEAVIFKTRKGVCAADPKERWRDMSK 88
 OY 61 HLDQIFONLKP 71
 ||| | ||
 DB 89 LDDQKSQTRKP 99

RESULT 3

Human precursor - human
 C:Species: Homo sapiens (man)
 C:Date: 01-Nov-1996 #sequence_revision 01-Nov-1996 #text_change 20-Jun-2000
 C:Accession: J04912
 R:Barthelemy, J.; Schueter, C.; Richter, E.; Noso, N.; Kulke, R.; Christophers, E.; Schroe-
 Biochem. Biophys. Res. Commun. 225, 1045-1051, 1996
 A:Title: Human dermal fibroblasts express eotaxin: Molecular cloning, mRNA expression, &
 A:Reference number: J04912; MUID:96374440
 A:Accession: J04912
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-97 <BAR>
 A:Cross-references: EMBL:Z75668; NID:G1531982; PIDN:CAA99997.1; PID:G1531983
 A:Experimental source: dermal fibroblast
 C:Comment: This protein has eosinophil specific chemotactic activity.
 C:Superfamily: macrophage inflammatory protein
 C:Keywords: fibroblast
 F:1-18/Domain: signal sequence #status predicted <SIG>
 F:19-97/Product: eotaxin #status predicted <MAT>

Query Match 70.7%; Score 270; DB 2; Length 97;
 Best Local Similarity 67.6%; Pred. No. 4.4e-24;
 Matches 48; Conservative 12; Mismatches 11; Indels 0; Gaps 0;

OY 1 SIPTCCFNVIRKIPICQLESTRTITNIOCPKEAVIFKTRKGVCAADPKERWRDMSK 60
 ||||||| :||| :||||| ||| :||||| ||||||| :||| :|||
 DB 27 SIPTCCFNVIRKIPICQLESTRTITNIOCPKEAVIFKTRKGVCAADPKERWRDMSK 86
 OY 61 HLDQIFONLKP 71
 ||| | ||
 DB 87 YLDQKSQTRKP 97

RESULT 4

monocyte chemoattractant protein 1 precursor - human
 N:Alternate names: GDCF-1; glioma-derived monocyte chemotactic factor 1; MCAF; MCP-1; m-
 N:Contains: glioma-derived chemotactic factor 2 (GDCF-2)
 C:Species: Homo sapiens (man)
 C:Date: 20-Feb-1993 #sequence_revision 20-Feb-1993 #text_change 16-Jul-1999
 C:Accession: A35474; A33476; S03339; I51841; A60299; A32300; A32396; A34561; I57488; J01
 R:Shyy, Y.J.; Li, Y.S.; Kolattukudy, P.E.
 Biochem. Biophys. Res. Commun. 169, 346-351, 1990
 A:Title: Structure of human monocyte chemotactic protein gene and its regulation by TPA.
 A:Reference number: A35474; MUID:90290466
 A:Accession: A35474
 A:Molecule type: DNA
 A:Residues: 1-99 <SHY>
 A:Cross-references: GB:M37719; NID:G187447; PIDN:AAA18102.1; PID:G487124
 R:Rollins, B.J.; Stier, P.; Ernst, T.; Wong, G.G.
 Mol. Cell. Biol. 9, 4687-4695, 1989
 A:Title: The human homolog of the JE gene encodes a monocyte secretory protein.

A:Reference number: A33476; MUID:90097880
 A:Accession: A33476

A:Molecule type: mRNA
 A:Residues: 1-99 <ROL>

A:Cross-references: GB:M30816; GB:M31625; GB:M31626; NID:G188701; PIDN:AAA36330.1; PI
 R:Yoshimura, T.; Yunoki, N.; Moore, S.K.; Appella, E.; Lerman, M.I.; Leonard, E.J.
 FEBS Lett. 244, 487-493, 1989
 A:Title: Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning,

A:Reference number: S03339; MUID:89153605
 A:Accession: S03339

A:Status: not compared with conceptual translation
 A:Molecule type: mRNA

A:Residues: 1-99 <YOS>

A:Cross-references: GB:X14768; NID:G34513; PIDN:CAA32876.1; PID:G34514
 R:Yoshimura, T.; Leonard, E.J.
 Adv. Exp. Med. Biol. 305, 47-56, 1991

A:Title: Human monocyte chemoattractant protein-1 (MCP-1).
 A:Reference number: I51841; MUID:92095166
 A:Accession: I51841

A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA

A:Residues: 1-99 <YOS>

A:Cross-references: GB:S71513; NID:G240867; PIDN:AA820651.1; PID:G240868
 R:Botzatz, B.; Colotta, F.; Sica, A.; Nobili, N.; Mantovani, A.
 Int. J. Cancer 45, 795-797, 1990

A:Title: A chemoattractant expressed in human sarcoma cells (tumor-derived chemotacti-
 -1/MCAF).
 A:Reference number: A60299; MUID:90216082
 A:Accession: A60299

A:Status: not compared with conceptual translation
 A:Molecule type: mRNA

A:Residues: 1-99 <BOT>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

A:Cross-references: GB:M24545; NID:G187434; PIDN:AAA18164.1; PID:G307163
 R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz
 Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989
 A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative
 A:Reference number: A32396; MUID:89184525
 A:Accession: A32396

A:Molecule type: protein
 A:Residues: X', 25-99 <ROB>

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 29, 2001, 13:55:35 ; Search time 13.82 Seconds

(without alignments)
175.987 Million cell updates/sec

Title: US-09-537-859-3

Perfect score: 382

Sequence: 1 SDPTCCFVINKKIPQRL.....ERWVDSMKHLQIQONLKP 71

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 93435 seqs, 34255486 residues

93435

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database : SwissProt.39.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	DB ID	Description
1	382	100.0	99 1 SY08_HUMAN	P80075 homo sapien
2	273	71.5	99 1 SY08_PIG	P49873 sus scrofa
3	267	69.9	97 1 E07A_HUMAN	P51671 homo sapien
4	255	66.8	99 1 SY08_BOVIN	O09141 bos taurus
5	246	64.4	99 1 SY02_HUMAN	P13500 homo sapien
6	239	62.6	101 1 SY02_CANFA	P52203 canis famill
7	237	62.0	99 1 SY02_PIG	P42831 sus scrofa
8	237	62.0	104 1 SY12_MOUSE	O62401 mus musculu
9	235	61.5	97 1 E07A_RAT	P97545 ratus norv
10	233	61.0	99 1 SY07_HUMAN	P80098 homo sapien
11	230	60.2	74 1 MCPB_BOVIN	P80343 bos sapien
12	229	59.9	97 1 E07A_MOUSE	P48298 mus musculu
13	219	57.3	96 1 E07A_CANPO	P80325 cavia porce
14	215.5	56.4	98 1 SY13_HUMAN	O99616 homo sapien
15	208	54.5	99 1 MCPA_BOVIN	P28291 bos taurus
16	207	54.2	148 1 SY02_MOUSE	P10148 mus musculu
17	206	53.9	125 1 SY02_RABIT	P28292 oryctolagus
18	196	51.3	148 1 SY02_RAT	P14844 ratus norv
19	189.5	49.6	120 1 SY02_CANPO	O08782 cavia porce
20	177.5	46.5	97 1 SY07_MOUSE	O03366 mus musculu
21	175.5	45.9	97 1 SY07_RAT	O90336 ratus norv
22	155.5	40.7	90 1 SY04_CHICK	O90826 gallus gall
23	151	39.5	119 1 SY24_HUMAN	O00175 homo sapien
24	149.5	39.1	93 1 SY14_HUMAN	O16627 homo sapien
25	149.5	39.1	93 1 SY14_HUMAN	P16619 homo sapien
26	142.5	37.3	92 1 SY03_HUMAN	P10147 homo sapien
27	138.5	36.3	92 1 SY04_HUMAN	P13236 h small ind
28	136.5	35.7	92 1 SY04_RABIT	P46632 oryctolagus
29	132.5	34.7	392 1 SY01_RAT	O55145 ratus norv
30	131.5	34.4	92 1 SY04_RAT	P50230 ratus norv
31	131.5	34.4	397 1 SY01_HUMAN	P78423 homo sapien
32	130.5	34.2	92 1 SY04_MOUSE	P14057 mus musculu
33	129	33.8	92 1 SY03_RAT	P50229 ratus norv

ALIGNMENTS

RESULT ID	SY08_HUMAN	STANDARD:	PRT:	99 AA.
AC	P80075; P78388;			
DT	01-DEC-1992 (Rel. 24, Created)			
DT	01-NOV-1997 (Rel. 35, Last sequence update)			
DT	01-OCT-2000 (Rel. 40, Last annotation update)			
DE	SMALL INDUCIBLE CYTOKINE A8 PRECURSOR (MONOCYTE CHEMOTACTIC PROTEIN 2)			
DE	(MCP-2) (MONOCYTE CHEMOTACTIC PROTEIN 2) (HC14).			
GN	SCYA8 OR SCYA10 OR MCP2.			
OS	Homo sapiens (human).			
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RX	SEQUENCE FROM N.A., AND VARIANT GLN-69.			
RA	MEDLINE=97237052; PubMed=9119400;			
RA	van Collie E., Fiten P., Nomiyama H., Sakaki Y., Miura R., Yoshie O.,			
RA	van Damme J., Opdenakker G.;			
RT	"The human MCP-2 gene (SCYA8): cloning, sequence analysis, tissue			
RT	expression, and assignment to the CC chemokine gene contig on			
RT	chromosome 17q11.2.";			
RL	Genomics 40:323-331(1997).			
RN	[2]			
RP	SEQUENCE FROM N.A., AND VARIANT GLN-69.			
RP	TISSUE=Bone marrow;			
RC	MEDLINE=97224420; PubMed=9070881;			
RX	van Collie E., Froyen F., Nomiyama H., Miura R., Fiten P.,			
RA	van Aelst I., van Damme J., Opdenakker G.;			
RT	"Human monocyte chemotactic protein-2: cDNA cloning and regulated			
RT	expression of mRNA in mesenchymal cells.";			
RT	Biochem. Biophys. Res. Commun. 231:726-730(1997).			
RN	[3]			
RP	SEQUENCE OF 23-99 FROM N.A.			
RX	MEDLINE=91207938; PubMed=2518726;			
RA	Chang H.C., Hsu F., Freeman G.J., Griffin J.D., Reinherz E.L.;			
RT	"Cloning and expression of a gamma-interferon-inducible gene in			
RT	monocytes: a new member of a cytokine gene family.";			
RL	Int. Immunol. 1:388-399(1989).			
RN	[4]			
RP	SEQUENCE OF 26-99.			
RC	TISSUE=Osteosarcoma;			
RX	MEDLINE=92308855; PubMed=1613466;			
RA	van Damme J., Proost P., Lenaerts J.-P., Opdenakker G.;			
RT	"Structural and functional identification of two human, tumor-derived			
RT	monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the			
RT	chemokine family.";			
RL	J. Exp. Med. 176:59-65(1992).			
RN	[5]			
RP	SUBUNIT.			
RX	MEDLINE=97053697; PubMed=8898111;			
RA	Kim K.-S., Rajaratnam K., Clark-Lewis I., Sykes B.D.;			
RT	"Structural characterization of a monomeric chemokine: monocyte			
RT	chemotactant protein-3.";			
RT	FEBS Lett. 395:277-282(1996).			
CC	-1- FUNCTION: CHEMOTACTIC FACTOR THAT ATTRACTS MONOCYTES, LYMPHOCYTES,			

34	128	33.5	92 1 SY03_MOUSE	P10855 mus musculu
35	127.5	33.4	94 1 SY26_HUMAN	O97528 homo sapien
36	127.5	33.4	114 1 SYC1_HUMAN	P47992 homo sapien
37	127.5	33.4	114 1 SYC1_HUMAN	O94922 homo sapien
38	125.5	32.9	395 1 SYD1_MOUSE	O35188 mus musculu
39	124.5	32.6	91 1 SY05_CANPO	P97272 cavia porce
40	123.5	32.3	89 1 SY18_HUMAN	P55774 h small ind
41	123.5	32.3	113 1 SY15_HUMAN	O16663 homo sapien
42	122.5	32.1	120 1 SY23_HUMAN	P55773 homo sapien
43	121.5	31.8	91 1 SY05_BOVIN	O97919 bos taurus
44	121.5	31.8	91 1 SY05_HUMAN	P13501 homo sapien
45	121.5	31.8	134 1 SY21_HUMAN	O00585 homo sapien

```

CC BASOPHILS AND EOSINOPHILS. MAY PLAY A ROLE IN NEOPLASIA AND
CC INFLAMMATORY HOST RESPONSES. THIS PROTEIN CAN BIND HEPARIN.
CC -1- SUBUNIT: MONOMER OR HOMODIMER. IN EQUILIBRIUM
CC -1- TISSUE SPECIFICITY: HIGHEST EXPRESSION FOUND IN THE SMALL
CC -1- INTERESTINE AND PERIPHERAL BLOOD CELLS. INTERMEDIATE LEVELS SEEN IN
CC -1- THE HEART, PLACENTA, LUNG, SKELETAL MUSCLE, THYMUS, COLON, OVARY,
CC -1- SPINAL CORD AND PANCREAS. LOW LEVELS SEEN IN THE BRAIN, LIVER,
CC -1- SPLEEN AND PROSTATE.
CC -1- INDUCTION: BY INTERFERON GAMMA, MITOGENS AND INTERLEUKIN-1.
CC -1- SIMILARITY: BELONGS TO THE INTERCRINE BETA FAMILY (SMALL CYTOKINE
CC -1- C-C) (CHEMOKINE CC).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: X99886; CAA68168.1; ALT_INT.
DR EMBL: Y10802; CAA71760.1; -.
DR EMBL: Y16645; CAA76341.1; -.
DR HSSP: P13500; IDOL.
DR MIM: 602283; -.
DR InterPro: IPR000827; -.
DR InterPro: IPR001811; -.
DR Pfam: PF00048; IL8; 1.
DR PROSITE: PS00472; SMALL_CYTOKINES_CC; 1.
DR Cytokine; Chemotaxis; Signal; Heparin-binding; Inflammatory response;
DR Polymorphism.
DR SIGNAL 1 23 PROBABLE.
FT CHAIN 24 99 SMALL INDUCIBLE CYTOKINE A8.
FT MOD_RES 24 24 PYRROLIDONE CARBOXYLIC ACID.
FT DISULFID 34 59 BY SIMILARITY.
FT DISULFID 35 75 BY SIMILARITY.
FT VARIANT 69 69 K -> Q.
FT SEQUENCE 99 AA; 11246 MW; 9D67976B9422F2A CRC64;
SO

```

Query Match 100.0%; Score 382; DB 1; Length 99;
Best Local Similarity 100.0%; Pred. No. 5.3e-38;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 SIPTCCFNVRNKRIPQRLQLESTYRTITNQCPKEAVIFKTRGKREVCADPKERWVDSMK 60
DB 29 SIPTCCFNVRNKRIPQRLQLESTYRTITNQCPKEAVIFKTRGKREVCADPKERWVDSMK 88
DB 61 HLDQIFQNLKP 71
DB 89 HLDQIFQNLKP 99

```

RESULT 2

SY08_PIG STANDARD; PRT; 99 AA.

AC P49873;

DT 01-OCT-1996 (Rel. 34, Last sequence update)

DT 15-JUL-1999 (Rel. 38, Last annotation update)

DE SMALL INDUCIBLE CYTOKINE A8 PRECURSOR (MONOCYTE CHEMOTACTIC PROTEIN 2)

DE (MCP-2) (MONOCYTE CHEMOTACTIC PROTEIN 2).

GN SCY8 OR MCP2.

OS Sus scrofa (Pig).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.

OX NCBI_Taxid=9823;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=95091716; PubMed=799015;

RA Hosang K.K., Knoke I.I., Klaudiny J.J., Wempe F.F., Wuttke W.W.,

RA Schell K.K.;

```

RT "Porcine luteal cells express monocyte chemoattractant protein-2
RT (MCP-2): analysis by cDNA cloning and northern analysis.";
RT Biochem. Biophys. Res. Commun. 205:148-153(1994).
CC -1- FUNCTION: CHEMOTACTIC FACTOR THAT ATTRACTS MONOCYTES. THIS PROTEIN
CC CAN BIND HEPARIN.
CC -1- SUBUNIT: MONOMER OR HOMODIMER. IN EQUILIBRIUM (BY SIMILARITY).
CC -1- SIMILARITY: BELONGS TO THE INTERCRINE BETA FAMILY (SMALL CYTOKINE
CC -1- C-C) (CHEMOKINE CC).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: Z48480; CAA88371.1; -.
DR HSSP: P80098; INCV.
DR InterPro: IPR000827; -.
DR InterPro: IPR001811; -.
DR Pfam: PF00048; IL8; 1.
DR PROSITE: PS00472; SMALL_CYTOKINES_CC; 1.
DR Cytokine; Chemotaxis; Signal; Heparin-binding; Inflammatory response.
FT SIGNAL 1 23 BY SIMILARITY.
FT CHAIN 24 99 SMALL INDUCIBLE CYTOKINE A8.
FT MOD_RES 24 24 PYRROLIDONE CARBOXYLIC ACID (BY
FT DISULFID 34 59 BY SIMILARITY.
FT DISULFID 35 75 BY SIMILARITY.
FT SEQUENCE 99 AA; 10903 MW; D3DA0F7A964CDB1 CRC64;
SO

```

Query Match 71.5%; Score 273; DB 1; Length 99;
Best Local Similarity 70.4%; Pred. No. 2.8e-25;
Matches 50; Conservative 10; Mismatches 11; Indels 0; Gaps 0;

```

QY 1 SIPTCCFNVRNKRIPQRLQLESTYRTITNQCPKEAVIFKTRGKREVCADPKERWVDSMK 60
DB 29 SIPTCCFNVRNKRIPQRLQLESTYRTITNQCPKEAVIFKTRGKREVCADPKERWVDSMK 88
DB 61 HLDQIFQNLKP 71
DB 89 HLDQIFQNLKP 99

```

RESULT 3

SY08_HUMAN STANDARD; PRT; 97 AA.

AC P51671; P50877; Q92490; Q92491;

DT 01-OCT-1996 (Rel. 34, Created)

DT 01-OCT-1996 (Rel. 34, Last sequence update)

DT 01-OCT-2000 (Rel. 40, Last annotation update)

DE EORAXIN PRECURSOR (EOSINOPHIL CHEMOTACTIC PROTEIN).

GN SCY11.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

OX NCBI_Taxid=9606;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=96181756; PubMed=8597956;

RA Garcia-Zepeda E.A., Rothenberg M.E., Ombey T.R., Leder P.,

RA Luster A.D.;

RT "Human eotaxin is a specific chemoattractant for eosinophil cells and

RT provides a new mechanism to explain tissue eosinophilia.";

RL Nat. Med. 2:449-456(1996).

RN [2]

RP SEQUENCE FROM N.A.

RX MEDLINE=96189937; PubMed=8609214;

RA Ponath P.D., Qin S., Ringler D.J., Clark-Lewis I., Wang J., Kassam N.,

RA Smith H., Shi X., Gonzalo J.A., Newman W., Gutierrez-Ramos J.C.,

RA Mackay C.R.;

